Dr. Agarwal’s Health Care Ltd sets 23-for-2 share exchange
Key highlights
- AHCL fixed November 18, 2026 as the record date for eligible AEHL shareholders under the amalgamation scheme.
- Eligible AEHL shareholders will receive 23 AHCL shares for every two AEHL shares, equal to 11.5 AHCL shares per AEHL share.
- The AHCL-AEHL Scheme of Amalgamation became effective from November 1, 2026.
- AHCL allotted 54,728 ESOP shares on November 5, 2026, taking paid-up shares to 31,70,99,111.
powered by IRIS

Dr. Agarwal’s Health Care Ltd has fixed November 18, 2026 as the record date for its amalgamation with Dr. Agarwal’s Eye Hospital Ltd, under which eligible shareholders will receive 23 AHCL shares for every two AEHL shares held. The scheme became effective from November 1, 2026, setting the terms for the consideration-share allotment.
Know Dr Agarwals Health Care inside out
Results, valuation, peers and who's buying, in one view.
What is the AHCL-AEHL share exchange arrangement?
Dr. Agarwal’s Health Care Ltd, referred to as AHCL, will issue 23 fully paid-up equity shares of face value ₹1 each for every two fully paid-up equity shares of Dr. Agarwal’s Eye Hospital Ltd, referred to as AEHL, of face value ₹10 each. The exchange ratio is equivalent to 11.5 AHCL shares for each AEHL share.
The consideration shares are being issued under the Scheme of Amalgamation between AHCL and AEHL. AHCL said the scheme had become effective and operative from November 1, 2026. The record date determines which AEHL shareholders qualify to receive AHCL shares under the approved arrangement.
The differing face values of the two companies' shares do not change the stated exchange ratio. Eligible investors' entitlement will be calculated from the AEHL shares held on the record date, according to the terms announced for the scheme.
When is the record date for AEHL shareholders?
November 18, 2026, a Wednesday, is the record date fixed by AHCL's board for determining eligible AEHL shareholders. Investors holding AEHL shares on that date will be considered for the allotment of AHCL consideration shares pursuant to the amalgamation.
The record date also applies to the amalgamation of Dr. Agarwal’s Eye Hospital into AHCL. The announcement does not provide a separate timetable for the actual credit or listing of the consideration shares, nor does it disclose the number of AHCL shares to be issued under the scheme.
For shareholders, the key disclosed terms are the November 1 effective date, the November 18 eligibility date, and the 23-for-2 exchange ratio. These details establish the corporate-action framework without indicating a market price, valuation impact, or post-amalgamation shareholding pattern.
How has AHCL's equity capital changed through ESOP allotments?
AHCL's paid-up equity capital rose to ₹31.71 crore, comprising 31,70,99,111 equity shares, after the allotment of 54,728 shares under its Employees Stock Option Scheme 2022. The Nomination and Remuneration Committee approved this allotment on November 5, 2026.
Before that allotment, AHCL had paid-up capital of ₹31.70 crore represented by 31,70,44,383 shares. The 54,728-share issuance was described as dilution of about 0.017%. The allotted shares have a face value of ₹1 each and were issued to eligible employees on exercise of vested options.
The November 5 allotment included 4,528 shares exercised at ₹84.93 each, 9,700 shares at ₹129.88 each, and 40,500 shares at ₹409.08 each. The disclosed total exercise proceeds were about ₹2.14 crore. AHCL had also allotted 18,200 ESOP shares on October 20, 2026, following approval by the committee.
Got a follow-up? Ask IRIS
What other employee share allotments has AHCL made?
AHCL has made several allotments under its 2022 employee stock option scheme during the period disclosed in its filings. These issues arose from employees exercising granted options and increased the number of issued equity shares over time.
The company allotted 1,59,865 shares on April 21, 2025, followed by 1,18,646 shares on May 14, 2025. It subsequently allotted 12,523 shares on October 30, 2025, 2,99,122 shares on December 12, 2025, and 3,37,504 shares on January 6, 2026.
On October 20, 2026, AHCL issued 18,200 shares of face value ₹1 each. That allotment included 8,200 shares exercised at ₹129.88 and 10,000 shares at ₹135.00. The shares were stated to rank pari passu with existing equity shares and had no lock-in period.
These ESOP issuances are separate from the consideration shares to be allotted for the AEHL amalgamation. The ESOP allotments reflect exercises under an employee incentive plan, while the merger-related share issue will be determined by the share exchange ratio and the eligible AEHL shareholding on the record date.
What does the amalgamation mean for shareholders and the market?
The amalgamation gives eligible AEHL shareholders an identified route into AHCL through the issue of AHCL equity shares at the announced 23-for-2 ratio. It is a corporate action that changes the form of their shareholding from AEHL shares to AHCL consideration shares, subject to eligibility on November 18.
For AHCL investors, the scheme will involve an issue of additional shares, although the announcement does not disclose the final number of shares to be allotted or the resulting dilution. The source also does not provide an AHCL share-price movement, an estimated transaction value, or financial projections linked to the amalgamation.
The recent ESOP issues provide context for changes in AHCL's outstanding equity capital before the merger-related allotment. The November 5 issue of 54,728 shares was small relative to the 31,70,99,111 shares outstanding afterward, but the eventual share count will also depend on the consideration shares issued to qualifying AEHL shareholders.
Conclusion
AHCL's announcement makes November 18, 2026 the key eligibility date for the amalgamation with AEHL. The central term is the issue of 23 AHCL shares for every two AEHL shares, while AHCL's separately disclosed ESOP activity has increased its paid-up share capital to 31,70,99,111 shares after the November 5 allotment.
The next disclosed milestone is the record date, which will establish the AEHL shareholders eligible for consideration shares. Investors can watch for further company disclosures on the number of shares allotted under the scheme, the timing of their credit, and the resulting paid-up capital after the amalgamation process.


